9 Matching Annotations
  1. Dec 2022
    1. Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease.

      One of the few papers giving clear support to ivermectin as a prophylactic drug against covid19.

      Has been partially refuted by politifact, and accused 1st author Andrew Bryant of hiding conflict-of-interest.

    1. There was however a marked reduction of self-reported anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.

      A well-structured research about non-severe case protocol pre-announced on Jun 2020 concludes that it reduces anosmia!

    1. Based on the very low-certainty evidence for inpatients, we are still uncertain whether ivermectin prevents death or clinical worsening or increases serious adverse events, while there is low-certainty evidence that it has no beneficial effect regarding clinical improvement, viral clearance and adverse events. No evidence is available on ivermectin to prevent SARS-CoV-2 infection.

      Study of trials by german researcher is dismissive of any therapeutic value.

    1. IvermectinThis FDA-approved antiparasitic drug has demonstrated a degree of efficacy in vitro against SARS-CoV-2 infection (Caly et al., 2020; Yang et al., 2020), and uncontrolled, interventional studies have reported a degree of efficacy or no benefits (Amhed et al., 2020; Chachar et al., 2020; Khan et al., 2020). However, the NIH Panel indicates that there is insufficient evidence for COVID-19 treatment and recommended against its use (COVID-19 Treatment Guidelines Panel, 2022).

      Big position-paper from Lincei Academy focusing mostly on other drugs, is NOT dismissive of ivermectin, provides x2 for in-vitro and x3 in-vivo refs, and repeats the FDA mantra at the end.

  2. Nov 2022
    1. Even though ivermectin had no effect on viral load, SARS-Cov-2-associated pathology was greatly attenuated. IVM had a sex-dependent and compartmentalized immunomodulatory effect, preventing clinical deterioration and reducing olfactory deficit in infected animals. Importantly, ivermectin dramatically reduced the Il-6/Il-10 ratio in lung tissue, which likely accounts for the more favorable clinical presentation in treated animals. Our data support IVM as a promising anti-COVID-19 drug candidate.

      Impressive pro-ivermectin results, but paper probably has low sciscore.

    1. In conclusion, ivermectin seems to be effective to diminish MHV viral load and disease in mice, being a useful model for further understanding new therapies against coronavirus diseases.

      Impressive result for ivermectine.

    1. Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

      That's the generic's equivalent for [[paxlovid]].